Federation Des Caisses Desjardins Du Quebec Ocugen, Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 14, 2024	SELL	$0.36 - $0.57 $180 - $285	-500 Closed	0 $0
Q4 2022 Aug 14, 2024	SELL	$1.11 - $1.87 $1,110 - $1,870	-1,000 Reduced 66.67%	500 $650,000
Q1 2022 Aug 14, 2024	BUY	$2.34 - $4.72 $3,510 - $7,080	1,500 New	1,500 $4.95 Million
Q4 2021 Aug 30, 2024	SELL	$4.38 - $15.67 $10,840 - $38,783	-2,475 Reduced 62.26%	1,500 $6.83 Million
Q3 2021 Aug 30, 2024	SELL	$6.36 - $8.51 $3,339 - $4,467	-525 Reduced 11.67%	3,975 $28.5 Million
Q2 2021 Aug 30, 2024	BUY	$5.52 - $15.68 $24,839 - $70,560	4,500 New	4,500 $36.1 Million
Q1 2021 Aug 30, 2024	BUY	$1.66 - $15.81 $2,498 - $23,794	1,505 New	1,505 $10.2 Million

Others Institutions Holding OCGN

# of Institutions

125

Shares Held

78.4M

Call Options Held

535K

Put Options Held

523K

View Full List

About Ocugen, Inc.

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $158M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

More about OCGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account